NIO752 A randomized, placebo-controlled, parallel group, 72-week study to evaluate the efficacy of NIO752 in participants with Progressive Supranuclear palsy followed by an Open Label Extension (CNIO752A12301 (PRESERVE))

Principal Investigator

Johannes Klein

Contact us

Email: dendron@ouh.nhs.uk

IRAS number

1012744